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Human breast cancer is a heterogeneous disease that shows a
significant amount of biological and histological diversity. Based
on the classification of the tumors by the gene expression pat-
terns derived from cDNA microarray assays, a hierarchical clus-
tering has been demonstrated for five major biologically distinct
subtypes; these subtypes are associated with significant differ-
ences of the clinical outcome and these subtypes include: lumi-
nal A, luminal B, human epidermal growth factor receptor-2
(HER2) overexpressing, basal-like and normal breast-like.1-3
Within these subtypes, HER2 overexpressing and basal-like
breast cancers have the worst prognosis as compared to the other
subtypes.2,3 Immunohistochemical surrogates for breast cancer
subtyping have been developed and used in the clinical setting4-7
and they include the estrogen receptor (ER), progesterone recep-
tor (PR), HER2, epidermal growth factor receptor-1 (EGFR),
c-KIT, basal (CK5/6, CK14, and CK17) and luminal (CK7/8,
CK18, and CK19) cytokeratins (CK).8
Among the five subtypes, the basal-like subtype has been
characterized by cDNA microarray profiling by a high expres-
sion of the genes that are associated with breast basal epithelial
cells, and the basal-like subtype is negative for ER, PR and
HER2 (the so-called ‘triple negative phenotype’) and positive
for basal CK, EGFR, and/or c-KIT, as determined by immuno-
histochemical analyses. The basal-like subtype and triple-nega-
tive breast cancer (TNBC) are not the same entity;9 however,
most basal-like subgroups are included in the TNBC category.
Therefore, the triple-negative (TN) phenotype is commonly
used as a clinical surrogate for basal-like tumors.10,11 Because
there is no expression of hormonal receptors (ER and PR) and
HER2, these basal-like tumors do not benefit from specific tar-
geted therapy such as hormonal treatment and trastuzumab
administration.
Ductal carcinoma in situ (DCIS) is generally regarded as a pre-
cancerous lesion that’s associated with the development of invasive
carcinoma. The association of TN with DCIS has been reported
in a few studies that have demonstrated the existence of a pure
DCIS with the basal phenotype12,13 and also a few cases of DCIS
that co-exist with TNBC. This suggests the possibility of a pre-
cursor lesion that might be associated with the development of
TNBC.14
Background : Triple-negative breast carcinomas (TNBCs) are associated with high-grade
histological tumor and a poor clinical outcome. In this study, we evaluated the histology and
immunohistochemical features of DCIS co-existing with TNBC to determine the characteristics
of the precursor lesions of TNBC. Methods : Among the 1,610 cases of breast carcinoma, we
selected the TNBCs with DCIS (n=196), and compared the pathological and immunohisto-
chemical findings of the DCIS with those of the invasive carcinoma areas. Results : Among
the 1,610 breast carcinomas, the TNBCs accounted for 330 cases (20.5%) and there were
196 cases with DCIS. The TN-DCIS cases exhibited high nuclear (94.5%) and histological
(94.5%) grades, comedo-necrosis (68.9%) and a small extent of the DCIS-involved area.
Immunohistochemically, a p53 expression was present in 48.4% of the TN-DCIS cases and
a high Ki-67 index was present in 31.5%. The same TN immunohistochemical profiles as the
carcinoma were detected in 109 of the 124 (87.9%) cases, but different profiles were observed
in 15 of the 124 (12.1%) cases. The 15 discordant cases were associated with a low histo-
logical grade (p=0.037), low p53-positivity (p=0.006) and a low Ki-67 index (p=0.026), as com-
pared to the invasive carcinomas. Conclusions : The results of this study suggest that TN
DCIS is a highly probable, but not obligate, precursor lesion of TNBC. 
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In this study, we classified the breast carcinomas of Korean
women into four subtypes with using the triple markers ER,
PR and HER2, and we determined the prevalence of each sub-
type and its association with DCIS. After the co-existence of
DCIS and TNBC was confirmed, we evaluated the histological
and immunohistochemical features of the DCIS co-existing with
the TNBC to determine the characteristic features of the pre-
cursor lesions that are associated with TNBC.
MATERIALS AND METHODS
Case selection
A total of 1,610 cases of breast carcinomas were collected by
reviewing the pathology reports of the patients who underwent
surgical breast resection at Seoul National University Hospital
from 2006 through 2007. In addition, the histological diagno-
sis, the nuclear and histological grades of invasive carcinomas
as assessed by a modified Bloom-Richardson system and the
presence/absence of DCIS were confirmed. All of the enrolled
patients were Korean women, and their mean age at surgery was
48.13 years (range of age 20-83 years). The collected breast car-
cinomas were classified into four subtypes (Luminal, Luminal/
HER2, HER2 and Triple-negative) according to the ER, PR
and HER2 expression status of the invasive tumor, based on the
immunohistochemical profiles at the time of the diagnosis: Lumi-
nal (ER+ and/or PR+, HER2-), Luminal/HER2 (ER+ and/or
PR+, HER2+), HER2 (ER- and PR-, HER2+), and Triple-neg-
ative (ER- and PR-, HER2-). The TN subtypes were identified
in 330 cases out of the total 1,610 cases. Among these TN sub-
types, the cases with DCIS (196 of 330 cases) were evaluated
for their histological and immunohistochemical features.
Histological evaluation of DCIS co-existing with TNBCs
Among 196 cases of TNBC with co-existing DCIS, the his-
tological features of the DCIS were reviewed in 164 cases. Thirty
cases were excluded due to having received preoperative che-
motherapy and two cases were unavailable. The tumors, includ-
ing DCIS, were consecutively embedded in paraffin at 5 mm
intervals for making measurements of the size of the invasive
carcinomas and the extent of the DCIS. The formalin-fixed,
paraffin-embedded tissue blocks were cut in 4 μm sections, and
then they were stained with hematoxylin and eosin. The nucle-
ar grade of the DCIS was assessed as two grades (low or high),
based on the nuclear size and regularity, the chromatin pattern,
the number and size of the nucleoli and the mitotic activity. The
histological grade of the DCIS was divided into three categories
according to the nuclear grade in combination with the presence/
absence of necrosis (according to the ‘‘Van Nuys pathologic clas-
sification’’): low (a low nuclear grade with no necrosis), inter-
mediate (a low nuclear grade with necrosis) and high (a high
nuclear grade with or without necrosis). The distribution of the
DCIS was classified into three categories: present within the
tumor and mixed with invasive carcinoma, present around the
tumor and present with both. The percentage of the DCIS in
the total tumor volume was estimated for the cases with the
DCIS present within the invasive carcinoma. When the DCIS
was present around the invasive carcinoma, the difference in
the greatest dimension between the invasive tumor only and
the tumor with the DCIS as well as the invasive carcinoma was
used to calculate the extent of the DCIS. This was then divided
into three sections: less than 1 cm, 1 cm or more and less than
2 cm, and 2 cm or more. Other histological features such as pres-
ence/absence of comedo-necrosis and microcalcification were
also evaluated.
Immunohistochemical evaluation of DCIS co-existing
with TNBCs
Immunohistochemical staining for ER, PR, HER2, p53 and
Ki-67 was routinely performed in all the breast carcinomas using
an automated immunostainer (Techmate 500 plus, DAKO A/S,
Copenhagen, Denmark) at the time of the diagnosis. The infor-
mation on the primary antibodies used in this study is listed in
Table 1. We used 3,3′-diaminobenzidine tetrahydrochloride
(DAB) for visualization of antibody/enzyme complexes and we
counterstained the samples with Mayer’s hematoxylin. Among
196 cases of TNBC with co-existing DCIS, immunohistochem-
ical re-examination was performed in the 124 available cases. 
For ER and PR, the receptor positive results were defined as
nuclear staining in 10% or more of the tumor cells. The HER2
overexpression was considered as moderate to strong membra-
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Antibody Clone Manufacturer Dilution
Antigen
retrieval
ER 1D5 DakoCytomation 1:50 Microwave oven 
PR PgR636 DakoCytomation 1:50 Microwave oven 
HER2 CB11 Novocastra 1:200 Microwave oven 
p53 DO7 DakoCytomation 1:800 Microwave oven
Ki-67 MIB-1 DakoCytomation 1:1,000 Microwave oven
Table 1. Information of primary antibodies used in this study
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nous staining in greater than 10% of the tumor cells, which was
equivalent to a score of 2+ or 3+ by the HercepTest protocol.15
The p53 expression was graded into five groups according to
the proportion of tumor cells with nuclear p53 staining as no
expression, positive in less than 25%, positive in 25% or more
and less than 50%, positive in 50% or more and less than 75%,
and positive in more than 75%; a positive p53 expression was
defined as positive results of 25% or higher. A high Ki-67 index
was defined as nuclear staining in more than 10% of the tumor
cells. 
Statistical analysis
The χ2 test and Fisher’s exact test were used to compare fre-
quencies in the contingency tables. A bivariate correlation anal-
ysis was used to compare the p53 and Ki-67 indexes of the car-
cinomas with those of the co-existing DCIS, and Pearson’s cor-
relation coefficient (r) was calculated for the p53 and Ki-67 index
between the carcinomas and the co-existing DCIS. A p-value of
≤0.05 was considered to be statistically significant. All the sta-
tistical analyses were carried out using SPSS 12.0 for Windows
(SPSS, Inc.).
RESULTS
Grouping of the breast carcinomas by the immunohisto-
chemical subtype using triple markers
The majority of the histology diagnoses were invasive ductal
carcinomas, not otherwise specified (NOS) (1412, 87.7%), fol-
lowed by microinvasive carcinomas (41, 2.5%), invasive lobu-
lar carcinomas (35, 2.2%), mixed invasive ductal and lobular
carcinomas (34, 2.1%), and mucinous carcinomas (31, 1.9%).
The categorization of the breast cancer and the frequency of DCIS
for each subtype are summarized in Table 2. TNBCs were pre-
sent in 330 of the 1,610 cases (20.55%), and co-existing DCIS
was observed in 196 out of the 330 cases (59.4% within the sub-
type). Co-existence of DCIS was frequently noted in the HER2-
positive group, including the luminal/HER2 and HER2 sub-
types (88.9% and 86.7% within the subtypes, respectively), and
this was relatively uncommon in the TN subtype (p<0.001). 
About half of the microinvasive carcinomas (21 cases) were
included in the HER2 subtype, and this was three times as many
compared to the other subtypes. Most of the invasive lobular
carcinomas, mixed invasive ductal and lobular carcinomas, muci-
nous carcinomas and tubular carcinomas were the luminal sub-
type; the metaplastic carcinomas and medullary carcinomas were
the TN subtype (Table 3). 
Histological features of DCIS co-existing withTNBCs
Most of the DCIS co-existing with the TNBC cases showed
high grade features for the nuclear (155, 94.5%) and histologi-
cal (155, 94.5%) grades (Fig. 1A, B). Among the 9 DCIS with
a low nuclear grade, 8 (88.9%) co-existed with invasive carci-
noma with a nuclear grade of 2, and only one case (11.1%) had
a nuclear grade of 3. On the other hand, the majority of the
DCIS with a high nuclear grade co-existed with grade 3 inva-
sive carcinomas (143 cases, 92.3%). Similarly, only 2 out of 9
(22.2%) histological low-grade DCIS were accompanied with
histological grade 3 invasive carcinoma, and 137 out of 155










Luminal 860 (53.4) 660 (76.7)
Luminal/HER2 217 (13.5) 193 (88.9)
HER2 203 (12.6) 176 (86.7)
Triple negative 330 (20.5) 196 (59.4)
Table 2. Prevalence of breast carcinoma and co-existing DCIS
Subtype
Subtype (% within diagnosis)




IDC 741 (52.5) 197 (14.0) 174 (12.3) 300 (21.2) 1,412 (87.7)
MIC 7 (17.1) 7 (17.1) 21 (51.2) 6 (14.6) 41 (2.5)
ILC 33 (94.3) 0 0 2 (5.7) 35 (2.2)
MDLC 31 (91.2) 3 (8.8) 0 0 34 (2.1)
MucC 28 (90.3) 2 (6.5) 0 1 (3.2) 31 (1.9)
IMPC 2 (13.3) 7 (46.7) 4 (26.7) 2 (13.3) 15 (0.9)
MetC 0 0 1 (8.3) 11 (91.7) 12 (0.7)
TC 10 (100) 0 0 0 10 (0.6)
IPC 5 (83.3) 1 (16.7) 0 0 6 (0.4)
MedC 0 0 0 5 (100) 5 (0.3)
ApoC 0 0 3 (75.0) 1 (25.0) 4 (0.2)
Miscella- 3 (60.0) 0 0 2 (40.2) 5 (0.3)
neous
Table 3. Prevalence of histologic diagnoses of breast carcino-
mas according to subtypes
L, luminal; L/H, luminal/HER2; H, HER2; TN, triple-negative; IDC, inva-
sive ductal carcinoma; MIC, microinvasive carcinoma; ILC, invasive
lobular carcinoma; MDLC, mixed ductal and lobular carcinoma; MucC,
mucinous carcinoma; IMPC, invasive micropapillary carcinoma; MetC,
metaplastic carcinoma; TC, tubular carcinoma; IPC, invasive papillary
carcinoma; MedC, medullary carcinoma; ApoC, apocrine carcinoma. 
histological grade 3 invasive carcinoma. Comedo-necrosis was
noted in 135 of 196 (68.9%) cases and this was found only in
the cases that exhibited a high nuclear grade; an intermediate
histological grade was not present in these cases. The majority
of the co-existing DCIS cases were distributed around invasive
tumors (103, 62.8%), some were within the tumor and mixed
with the invasive carcinoma (33, 20.1%), and the remainder
(28, 17.1%) were distributed both around and mixed with the
invasive tumors. When the DCIS samples were noted to be with-
in the invasive tumor (n=61), a number of DCIS cases (40, 65.6%)
occupied less than 5% of the total tumor volume, and more than
90% of the DCIS cases occupied less than 25% of the total tumor
volume. When the DCIS cases were identified around the inva-
sive tumors (n=131), the difference in the greatest dimension
of the tumors, between invasive carcinoma only and the inva-
sive carcinoma and the DCIS, was calculated as described above;
it was less than 1 cm in 36 (48.1%) cases and 2 cm or more in
36 (27.5%) cases. Microcalcifications of the DCIS were identi-
fied in 46 (28.4%) cases, and this was associated with the pres-
ence of comedo-necrosis (p=0.008) and a high histological grade
(p=0.012).
Immunohistochemical comparison of DCIS co-existing
with TNBCs
p53 overexpression of DCIS was found in 60 of 124 (48.4%)
cases, and a high Ki-67 index was found in 39 of 124 (31.5%)
cases (Fig. 1C, D). The p53 expression of co-existing DCIS
strongly correlated with that of the invasive carcinoma (r=0.968,
p<0.001). In addition, the Ki-67 index of the DCIS and that of
the invasive carcinoma were also correlated (r=0.809, p<0.001).
The immunohistochemical TN phenotype, which was identi-
cal to the corresponding carcinomas, was noted in most of the
DCIS (109, 87.9%). However, different phenotypes were found
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Fig. 1. (A) DCIS co-existing with triple-negative breast carcinoma is identified around the invasive triple-negative breast carcinoma. (B)
This DCIS shows high grade nuclear features and comedo-necrosis. (C) p53 is highly expressed in the DCIS (nearly 100%). (D) Ki-67
index is about 40% in the DCIS.
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in 15 cases; 12 had a luminal subtype (Fig. 2A, B) and three a
HER2 subtype (Fig. 2C, D). On comparison of the immuno-
histochemical concordant cases with the discordant cases (Table
4), a low histological grade of the co-existing TNBC was more
commonly observed in the discordant cases than that in the con-
cordant cases (33.3% vs 11.0%, respectively, p=0.037). How-
ever, there was no significant difference observed in the histo-
logical grade of the DCIS between the discordant and concor-
dant cases (p=0.481). On the other hand, the discordant cases
were significantly associated with low p53-positive results (86.7%,
p=0.006) and a low Ki-67 index (86.7%, p=0.026) for the co-
existing carcinomas, and there was a tendency for low p53-pos-
itivity (73.3%, p=0.099) and a low Ki-67 index (86.7%, p=
0.142) for DCIS, with a marginal significance. A large extent
of the DCIS and the presence of microcalcification were observed
more frequently in the discordant cases (p=0.010 and 0.001,
respectively) than that in the concordant cases.
DISCUSSION
The recent studies that used cDNA microarray profiling have
demonstrated five distinctive subtypes of breast cancer that have
significant differences in their immunophenotype and clinical
outcomes.1-5 Among these five subtypes, the basal-like subtype
is associated with a larger size, a higher histological grade, push-
ing margins, a poorer Nottingham Prognostic Index, the devel-
opment of disease recurrence and distant metastasis,10,16,17 as well
as having a p53 expression.5,7
The basal-like subtype accounts for 17-37% of all breast can-
cers according to the classification based on cDNA microarray
profiling.3 Although there are some differences of the immuno-
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Fig. 2. (A) The DCIS with triple negative carcinoma shows high-grade histology. (B) Nuclear staining of ER is negative in the triple nega-
tive invasive carcinoma with weak cytoplasm staining (left), but strong positive results in the co-existing DCIS (right). (C) High grade DCIS
around the tumor shows comedo-necrosis. (D) HER2 staining is negative in the triple negative invasive carcinoma (left), but moderate to
strong membranous staining of the HER2 is noted in the DCIS (right).
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histochemical definitions of the subtypes and the subjects includ-
ed in each study, many studies using an immunohistochemical
classification of breast carcinoma have reported a basal-like sub-
type that expresses basal CK or EGFR in 9-20% of all breast
cancer cases.4-6,18 TNBC, with or without a basal CK and/or
EGFR expression, has been reported to account for 16-37% of
all breast cancer cases.6,9,14 The epidemiology studies reported
by Carey et al.5 and Millikan et al.18 used a classification that
included the basal-like subtype that expressed basal CK and/or
EGFR instead of the TN classification; the prevalence of TNBC,
as calculated from the reported data, was 26.4% and 26.3%,
respectively, for each study. Moreover, the data from these stud-
ies revealed that the basal-like subtype is a frequent finding (39%
and 27.2% respectively) in premenopausal African American
women. The only reported study on Korean women19 used the
immunohistochemical definition provided by Nielsen et al.,4
and the authors of that study classified the breast cancers as 15.9%
with the basal subtype and 23.7% with a negative subtype.
Because the definition reported by Nielsen et al. does not include
the PR status, the classification of ER-/PR+ breast cancers was
different from that used by our study. There are a number of
common characteristics in the TNBCs and basal-like subtypes;
the TN phenotype is considered to be a simple clinical surrogate
for the basal-like subtype, but they are not exactly the same.9,20
Recent studies have demonstrated that the tumors expressing
CK5/6 and/or EGFR persistently have a poorer prognosis; there-
fore, the use of the available five markers for the definition, includ-
ing ER, PR, HER2, CK5/6 and EGFR, would likely be more
useful for the predicting the prognosis than the TN definition
alone.6,16
As previously reported, some histology diagnoses were asso-
ciated with a specific immunohistochemical subtype. The typi-
cal ER-expressing tumors such as invasive lobular carcinomas,
tubular carcinomas and mucinous carcinomas have been includ-
ed in the luminal subtype, and most metaplastic carcinomas and
medullary carcinomas have been included in the TN subtype.21,22
A higher proportion of the HER2 subtype has been noted in
microinvasive carcinomas. This is thought to be due to the fact
that microinvasive carcinomas are more than 90% composed of
DCIS, and the HER2 overexpression in DCIS is more frequent
than that in invasive carcinomas. 
The overall prevalence of DCIS co-existing with breast carci-
noma was 76.1% (1,225 of 1,610 cases), and this was relatively
low for the TN subtype (196 of 330 cases, 59.4%). Most of the
DCIS co-existing with TNBC showed high grade histology, and
a small extent of the DCIS. The p53 expression and the Ki-67
index of the DCIS correlated with that of the co-existing TNBC,
as did the TN immunoprofile. In the prior studies of pure DCIS
with the basal-like subtype, a significant low prevalence (6-8%)
and high grade histology were also noted;12,13 a few studies have
reported that most cases with DCIS shared the same immuno-
histochemical features as co-existing carcinomas.14,23 It is rea-
sonable to assume that a precancerous DCIS and the breast car-
cinoma that develops from the DCIS would share similar histo-
logical and biological features; these features might be trans-
ferred from the DCIS to the invasive carcinoma. Therefore, the
TN DCIS is thought to be a highly probable precursor lesion
of triple-negative breast carcinoma. In addition, a prior study








Nuclear grade of carcinoma
2 11 (10.1) 4 (26.7) 0.085a
3 98 (89.9) 11 (73.3)
Histological grade of carcinoma
1 or 2 12 (11.0) 5 (33.3) 0.037a
3 94 (86.2) 10 (66.7)
Unknown 3 (2.8) 0
p53 positivity of carcinoma
≥25% 56 (51.4) 2 (13.3) 0.006a
<25% 53 (48.6) 13 (86.7)
Ki-67 index of carcinoma
≥10% 48 (44.0) 2 (13.3) 0.026a
<10% 61 (56.0) 13 (86.7)
Nuclear grade of DCIS
Low 4 (3.7) 1 (6.7) 0.481a
High 105 (96.3) 14 (93.3)
Histological grade of DCIS
Low 4 (3.7) 1 (6.7) 0.481a
High 105 (96.3) 14 (93.3)
p53 positivity of DCIS
≥25% 56 (51.4) 4 (26.7) 0.099a
<25% 53 (48.6) 11 (73.3)
Ki-67 index of DCIS
≥10% 37 (33.9) 2 (13.3) 0.142a
<10% 72 (66.1) 13 (86.7)
Extent of DCIS
<1 cm 41 (37.6) 1 (6.7) 0.010b
1 cm and <2 cm 18 (16.6) 6 (40.0)
≥2 cm 25 (22.9) 8 (53.3)
Undetermined 25 (22.9) 0
Microcalcification of DCIS
Present 29 (26.6) 11 (73.3) 0.001a
Absent 80 (73.4) 4 (26.7)
Table 4. Comparison between immunohistochemical concor-
dant and discordant cases
a, Fisher’s exact test; b, χ2 test.
reported that poorly differentiated invasive ductal carcinoma
typically had little or no associated DCIS because of a rapid dis-
ease progression; these carcinomas would be included in the
basal-like subtype.12 It is thought that the low prevalence and
small extent of the DCIS, with the co-existing TNBC, results
from the aggressive and rapidly progressive features of the TN
subtype. 
There are two models that explain the evolution of invasive
breast carcinoma from DCIS: ‘‘the theory of linear progression’’ and
‘‘the theory of parallel disease’’.24 The multistep linear progression
model describes that an invasive carcinoma develops from a low-
grade DCIS to a high-grade DCIS by a ‘‘linear pattern’’, and
this model is supported by many studies, including the recent
report by Allred et al. They reported that multiple histological
grades, biomarker phenotypes and intrinsic subtypes often coex-
ist within the same DCIS, and these diverse regions probably
compete for dominance, and eventually the most aggressive or
poorly differentiated area prevails. This concept supports the
development of well-differentiated DCIS to poorly differentiat-
ed DCIS, and this due to randomly acquired genetic defects. In
the parallel model, on the other hand, low-grade invasive carci-
noma tends to develop from a low-grade DCIS, and high-grade
invasive carcinoma tends to develop from a high-grade DCIS;
the majority of the molecular changes observed in the invasive
carcinoma are evident in the DCIS. Our study identified 15
cases (12.1%) of DCIS that had a different immunophenotype
from the co-existing TNBC. These discordant cases might be
compatible with lesions showing the diversity of DCIS as report-
ed by Allred; however these cases only accounted for a few cases.
Most of the DCIS co-existing with TNBC expressed high grade
histological features and the TN phenotype. According to the
parallel model, most of the cases of invasive carcinoma with a
histological high grade and the TN phenotype would be deter-
mined by the precancerous DCIS. Therefore, in the cases with
TNBC, a high-grade DCIS with the TN phenotype would be
considered to be a highly probable precursor lesion of the TNBC
by the parallel model, but not by the linear model. 
In summary, TNBCs were observed in about 20% of the total
cases of breast carcinomas and they were composed mainly of
invasive ductal carcinoma, NOS. Most of the medullary carci-
nomas and metaplastic carcinomas were also included in the
TNBC. We observed a lower prevalence and a small extent of
the DCIS co-existing with the TNBC, compared to the other
subtypes of breast cancer. Most DCIS with TNBC exhibited a
similar high grade histology with the co-existing carcinoma as
well as a similar immunohistochemical TN phenotype, yet a
few cases with different immunophenotypes were also noted.
Therefore, the TN DCIS is a highly probable, but not obligato-
ry, precursor lesion of TNBC.
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